Tiger Oil & Energy, Inc. TGRO
For those of you who may have missed yesterday’s morning and afternoon reports on TGRO, the stock had a marquee day, putting up one of the best performances in the whole of the OTC Markets.
On more than 20x the 3mo. average volume, TGRO bulled its way upward throughout the day, starting at a low of .36 and reaching as high as .524, good for a strong intraday move and chance for up to a 46% profit. A strong close at .52 effectively puts us on the lookout for continued momentum this morning, though as always, traders should use caution on a stock that has seen such rapid increases.
Our timely mention of TGRO (coming just a day after the stock woke up from the dead) also put us at the top of Monday’s Penny Stock Rumble:
WMI Holdings Corp. WMIH
WMIH appeared on our Blue Horseshoe Stocks blog with yesterday afternoon’s alert, at which time the stock was trading in the 1.42 area. It would go on to experience a 27% move to 1.81 in the final hours of the session.
WMIH is now heading into uncharted territory, being the highest it’s ever been. We are going to be cautious for a pullback, and in that event we’d like to see the previous resistance, our alert price of 1.42, hold as support.
SEATTLE, Dec. 9, 2013 /PRNewswire/ – WMI Holdings Corp. (WMIH) (“WMI” or the “Company”) today announced that KKR & Co. L.P. has entered into a conditional commitment letter to make a strategic investment in the Company (the “Commitment Letter”), dated December 8, 2013. >>>Read Release
BG Medicine, Inc. BGMD
We’ve also got a new item for your tickers this morning. BGMD has news out, and looks set for an interesting session as the stock is gapping up in pre-market trading, coming off of recent lows and breaking above the 50DMA (.64), a recent area of resistance.
We’ll be monitoring BGMD today as it reacts to this morning’s announcement:
WALTHAM, Mass., Dec 10, 2013 (GLOBE NEWSWIRE via COMTEX) — BG Medicine, Inc. (Nasdaq:BGMD) announced today that the Centers for Medicare and Medicaid Services (CMS) have published the final determination of the 2014 Medicare national limitation amount for the Company’s galectin-3 blood test (analyte-specific CPT(R) Code 82777) at the amount of a crosswalked test (analyte-specific CPT(R) Code 84244) whose 2014 national limitation amount is $30.01. This national limitation amount will replace the galectin-3 blood test’s national limitation amount of $17.80 that was effective in 2013.
The following are plays with FDA-related news out this morning that we’ll want to watch closely today:
Zogenix, Inc. ZGNX
FDA Approval News out this morning, monitoring for potential breakout. >>>View PR
Navidea Biopharmaceuticals, Inc. NAVB
FDA has granted “Fast Track” status for the company’s lymph node detection test. >>>View PR
GERN, ARIA, CNDO, RMBS, VTNC, BLRX, NWBO